| Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone - Additional data from a phase 3 trial.Oral Oncol | PMID 34560383无 PMCID | 2021-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial.Eur J Cancer | PMID 34563992无 PMCID | 2021-Nov | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Quality assurance program and early toxicities in the phase III BONBIS randomized trial evaluating the role of a localized radiation boost in ductal carcinoma in situ.Radiother Oncol | PMID 34571090无 PMCID | 2021-Nov | 0.90 | While this is a report from a definitive phase III randomized oncology trial in humans, it does not include the required survival, progression, recurrence, death, or time-to-event efficacy outcomes. It reports on quality assurance and acute toxicities only. | 待处理 |
| Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.Eur J Cancer | PMID 34571336PMC9350885 | 2021-Nov | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Weight loss and its impact on outcome in head and cancer patients during chemo-radiation.Oral Oncol | PMID 34571463无 PMCID | 2021-Nov | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.Eur J Cancer | PMID 34597975无 PMCID | 2021-Nov | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.Lancet Oncol | PMID 34600602PMC9377412 | 2021-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Impact of body-mass index on treatment and outcome in locally advanced rectal cancer: A secondary, post-hoc analysis of the CAO/ARO/AIO-04 randomized phase III trial.Radiother Oncol | PMID 34619239无 PMCID | 2021-Nov | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.Lancet HIV | PMID 34648734无 PMCID | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G.Cancer Med | PMID 34655175PMC8559492 | 2021-Nov | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.Lancet Oncol | PMID 34655533无 PMCID | 2021-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.Lancet Oncol | PMID 34656227PMC8560642 | 2021-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study.BioDrugs | PMID 34657274PMC8520467 | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.Lancet Glob Health | PMID 34678198PMC8551681 | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study.Target Oncol | PMID 34687398PMC8613117 | 2021-Nov | 0.85 | This is a report of a Phase Ib study component of a larger trial, not a definitive Phase III/IIIb or Phase II/III report. The primary endpoints were safety (dose-limiting toxicities) and objective response (ORR/CR/PR), not a time-to-event efficacy endpoint like OS or PFS. The study was discontinued before the Phase III component was initiated. | 待处理 |
| Measuring treatment response to advance precision medicine for multiple sclerosis.Ann Clin Transl Neurol | PMID 34704393PMC8607451 | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Achieving efficacy in subjects with sustained pegvaliase-neutralizing antibody responses.Mol Genet Metab | PMID 34716085无 PMCID | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2).Drugs | PMID 34724172PMC8602154 | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Intra-Articular Injection of a Novel DVS Cross-Linked Hyaluronic Acid Manufactured by Biological Fermentation (YYD302) in Patients With Knee Osteoarthritis: A Double-Blind, Randomized, Multicenter, Noninferiority Study.Clin Ther | PMID 34736768无 PMCID | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial.Nat Med | PMID 34737452无 PMCID | 2021-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Timing and durability of response to erenumab in patients with episodic migraine.Headache | PMID 34841526无 PMCID | 2021-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy.JCO Precis Oncol | PMID 34994614无 PMCID | 2021-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.J Hematol Oncol | PMID 34717692PMC8556975 | 2021-Oct-30 | 0.95 | The study is an eligible oncology Phase III randomized trial with a drug intervention, but the reported efficacy endpoints are safety (DLTs, TLS) and response rates (ORR, CR), not time-to-event survival endpoints (e.g., OS, PFS) required for inclusion in the KM digitization cohort. | 待处理 |
| A Protective Role for Arachidonic Acid Metabolites against Advanced Colorectal Adenoma in a Phase III Trial of Selenium.Nutrients | PMID 34836131PMC8621008 | 2021-Oct-29 | 0.85 | This is a Phase III randomized trial of selenium (a dietary supplement) for colorectal adenoma prevention. However, the abstract describes a biomarker analysis (oxylipins) within the trial, not a primary time-to-event efficacy endpoint. The outcomes are odds ratios for adenoma characteristics at baseline and associations with new adenoma development during follow-up, but no time-to-event analysis (KM, HR, OS/PFS/DFS/etc.) is mentioned. The intervention (selenium) is a dietary supplement, not a conventional drug. Therefore, it does not meet the required criteria for a time-to-event efficacy endpoint or a drug-containing intervention. | 待处理 |
| Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM).Kidney360 | PMID 35372979PMC8785778 | 2021-Oct-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.Vaccine | PMID 34620531PMC8461222 | 2021-Oct-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.Blood | PMID 34157093PMC9710469 | 2021-Oct-21 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.J Clin Endocrinol Metab | PMID 34272849PMC8530727 | 2021-Oct-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.N Engl J Med | PMID 34525276PMC8461567 | 2021-Oct-21 | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.Neurology | PMID 34433679PMC9246083 | 2021-Oct-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of a single intra-articular injection of a novel enhanced protein solution (JTA-004) compared to hylan G-F 20 in symptomatic knee osteoarthritis: a randomized, double-blind, controlled phase II/III study.BMC Musculoskelet Disord | PMID 34666767PMC8527807 | 2021-Oct-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial.Clin Cancer Res | PMID 34083233无 PMCID | 2021-Oct-15 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer.Clin Cancer Res | PMID 34326132PMC9401493 | 2021-Oct-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).Vaccine | PMID 34489128无 PMCID | 2021-Oct-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial.Signal Transduct Target Ther | PMID 34650034PMC8517012 | 2021-Oct-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII).BMC Cancer | PMID 34654402PMC8518265 | 2021-Oct-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy of a Cell-Culture-Derived Quadrivalent Influenza Vaccine in Children.N Engl J Med | PMID 34644472无 PMCID | 2021-Oct-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.J Am Coll Cardiol | PMID 34620410无 PMCID | 2021-Oct-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011).J Clin Oncol | PMID 34156881无 PMCID | 2021-Oct-10 | 0.85 | The report is a secondary analysis from a definitive randomized Phase III oncology trial, but its outcomes (gonadal function, fertility) are not survival, progression, recurrence, death, or other time-to-event efficacy measures required for inclusion in this cohort. | 待处理 |
| Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.J Clin Oncol | PMID 34379443PMC8500603 | 2021-Oct-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study.BMC Psychiatry | PMID 34625041PMC8501701 | 2021-Oct-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.N Engl J Med | PMID 34260849PMC8314785 | 2021-Oct-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.Nat Commun | PMID 34615860PMC8494913 | 2021-Oct-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of a Naphthoquine-Azithromycin Coformulation for Malaria Prophylaxis in Southeast Asia: A Phase 3, Double-blind, Randomized, Placebo-controlled Trial.Clin Infect Dis | PMID 32687174PMC8492115 | 2021-Oct-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET).Clin Infect Dis | PMID 32897367PMC8492220 | 2021-Oct-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.J Am Coll Cardiol | PMID 34593120无 PMCID | 2021-Oct-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinically- versus serologically-identified varicella: A hidden infection burden. A ten-year follow-up from a randomized study in varicella-endemic countries.Hum Vaccin Immunother | PMID 34181506PMC8437481 | 2021-Oct-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial.Crit Care | PMID 34600585PMC8487337 | 2021-Oct-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cyclophosphamide-Free Adjuvant Chemotherapy for Ovarian Protection in Young Women With Breast Cancer: A Randomized Phase 3 Trial.J Natl Cancer Inst | PMID 33822134PMC8486325 | 2021-Oct-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531.J Clin Oncol | PMID 34048275PMC8478392 | 2021-Oct-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |